These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2452218)

  • 1. From the World Health Organization. Current approaches to the development of dengue vaccines and related aspects of the molecular biology of flaviviruses.
    Brandt WE
    J Infect Dis; 1988 May; 157(5):1105-11. PubMed ID: 2452218
    [No Abstract]   [Full Text] [Related]  

  • 2. From the World Health Organization. Development of dengue and Japanese encephalitis vaccines.
    Brandt WE
    J Infect Dis; 1990 Sep; 162(3):577-83. PubMed ID: 1696952
    [No Abstract]   [Full Text] [Related]  

  • 3. Identifying Attenuating Mutations: Tools for a New Vaccine Design against Flaviviruses.
    Khou C; Pardigon N
    Intervirology; 2017; 60(1-2):8-18. PubMed ID: 28869941
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of dengue virus and the development of a vaccine.
    Murrell S; Wu SC; Butler M
    Biotechnol Adv; 2011; 29(2):239-47. PubMed ID: 21146601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tick-borne Langat/mosquito-borne dengue flavivirus chimera, a candidate live attenuated vaccine for protection against disease caused by members of the tick-borne encephalitis virus complex: evaluation in rhesus monkeys and in mosquitoes.
    Pletnev AG; Bray M; Hanley KA; Speicher J; Elkins R
    J Virol; 2001 Sep; 75(17):8259-67. PubMed ID: 11483771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA vaccines for flaviviruses.
    Putnak R; Porter K; Schmaljohn C
    Adv Virus Res; 2003; 61():445-68. PubMed ID: 14714440
    [No Abstract]   [Full Text] [Related]  

  • 7. Arguments for live flavivirus vaccines.
    de Silva A; Messer W
    Lancet; 2004 Aug 7-13; 364(9433):500. PubMed ID: 15302188
    [No Abstract]   [Full Text] [Related]  

  • 8. The neurovirulence of flaviviruses in crab-eating monkeys (Macaca fascicularis).
    Angsubhakorn S; Moe JB; Latendresse JR; Ward GS; Ngamprochana M; Sahaphong S; Bhamarapravati N
    Southeast Asian J Trop Med Public Health; 1986 Dec; 17(4):604-12. PubMed ID: 3033834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current status of dengue vaccines and prospects for the future.
    Bancroft WH
    P R Health Sci J; 1987 Apr; 6(1):23-6. PubMed ID: 3615797
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tropical diseases. Hunt for dengue vaccine heats up as the disease burden grows.
    Normile D
    Science; 2007 Sep; 317(5844):1494-5. PubMed ID: 17872423
    [No Abstract]   [Full Text] [Related]  

  • 11. Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates.
    Guirakhoo F; Weltzin R; Chambers TJ; Zhang ZX; Soike K; Ratterree M; Arroyo J; Georgakopoulos K; Catalan J; Monath TP
    J Virol; 2000 Jun; 74(12):5477-85. PubMed ID: 10823852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting.
    Chambers TJ; Tsai TF; Pervikov Y; Monath TP
    Vaccine; 1997 Oct; 15(14):1494-502. PubMed ID: 9330458
    [No Abstract]   [Full Text] [Related]  

  • 13. Technology evaluation: ChimeriVax-DEN, Acambis/Aventis.
    Jones T
    Curr Opin Mol Ther; 2004 Aug; 6(4):443-50. PubMed ID: 15468603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command.
    Innis BL; Eckels KH
    Am J Trop Med Hyg; 2003 Dec; 69(6 Suppl):1-4. PubMed ID: 14756126
    [No Abstract]   [Full Text] [Related]  

  • 15. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.
    Huang CY; Butrapet S; Tsuchiya KR; Bhamarapravati N; Gubler DJ; Kinney RM
    J Virol; 2003 Nov; 77(21):11436-47. PubMed ID: 14557629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virulence of a live dengue virus vaccine candidate: a possible new marker of dengue virus attenuation.
    Innis BL; Eckels KH; Kraiselburd E; Dubois DR; Meadors GF; Gubler DJ; Burke DS; Bancroft WH
    J Infect Dis; 1988 Oct; 158(4):876-80. PubMed ID: 3171230
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular and serologic markers of acute dengue infection in naive and flavivirus-vaccinated travelers.
    Domingo C; de Ory F; Sanz JC; Reyes N; Gascón J; Wichmann O; Puente S; Schunk M; López-Vélez R; Ruiz J; Tenorio A
    Diagn Microbiol Infect Dis; 2009 Sep; 65(1):42-8. PubMed ID: 19679234
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection.
    Ali M; Pandey RK; Khatoon N; Narula A; Mishra A; Prajapati VK
    Sci Rep; 2017 Aug; 7(1):9232. PubMed ID: 28835708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Flaviviruses and flavivirus vaccines.
    Heinz FX; Stiasny K
    Vaccine; 2012 Jun; 30(29):4301-6. PubMed ID: 22682286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of dengue viruses and some other flaviviruses by cDNA-RNA hybridization analysis and detection of a close relationship between dengue virus serotype 2 and Edge Hill virus.
    Blok J; Henchal EA; Gorman BM
    J Gen Virol; 1984 Dec; 65 ( Pt 12)():2173-81. PubMed ID: 6210345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.